What are the best ways to use HIF2-alpha inhibitors, specifically belzutifan, in individuals with advanced renal cell carcinoma? We know from the LITESPARK-004 study that we are seeing reasonable response rates. We’re seeing some benefit in about two-thirds of patients. So this is definitely an option as monotherapy in individuals who’ve received prior lines of therapy...
What are the best ways to use HIF2-alpha inhibitors, specifically belzutifan, in individuals with advanced renal cell carcinoma? We know from the LITESPARK-004 study that we are seeing reasonable response rates. We’re seeing some benefit in about two-thirds of patients. So this is definitely an option as monotherapy in individuals who’ve received prior lines of therapy. The big question is what do you combine this with? Do you combine it with a TKI? Do you combine it with immunotherapy? We are learning from certain studies that have been done now by Merck that perhaps combining immunotherapy may not be the optimal choice in the refractory setting. We have several registrational studies that are underway both from Merck and from Arcus looking at combinations with TKIs and we’re going to expect the one from Merck to read out in the next year or so. And there’s also the study from Arcus looking at cabozantinib together with HIF2-alpha inhibitor casdatifan. So I think we’re just going to need to see whether or not these sort of empiric exercises have value and I think we need to do a lot of science to understand what is the best dense partner for HIF2-alpha inhibitors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
